- Home
- NVS vs MRK Comparison
NVS vs MRK Comparison
Compare NVS & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVS
- MRK
- Stock Information
- Founded
- NVS 1895
- MRK 2000
- Country
- NVS Switzerland
- MRK United States
- Employees
- NVS N/A
- MRK N/A
- Industry
- NVS Biotechnology: Pharmaceutical Preparations
- MRK Biotechnology: Pharmaceutical Preparations
- Sector
- NVS Health Care
- MRK Health Care
- Exchange
- NVS Nasdaq
- MRK Nasdaq
- Market Cap
- NVS 230.5B
- MRK 218.2B
- IPO Year
- NVS 1991
- MRK N/A
- Fundamental
- Price
- NVS $115.75
- MRK $76.82
- Analyst Decision
- NVS Hold
- MRK Buy
- Analyst Count
- NVS 6
- MRK 15
- Target Price
- NVS $123.67
- MRK $113.71
- AVG Volume (30 Days)
- NVS 1.7M
- MRK 14.7M
- Earning Date
- NVS 07-17-2025
- MRK 04-24-2025
- Dividend Yield
- NVS 3.45%
- MRK 4.22%
- EPS Growth
- NVS N/A
- MRK 667.14
- EPS
- NVS 6.38
- MRK 6.88
- Revenue
- NVS $53,222,000,000.00
- MRK $63,922,000,000.00
- Revenue This Year
- NVS $7.22
- MRK $2.42
- Revenue Next Year
- NVS $1.94
- MRK $5.64
- P/E Ratio
- NVS $17.41
- MRK $11.17
- Revenue Growth
- NVS 11.50
- MRK 4.10
- 52 Week Low
- NVS $96.06
- MRK $73.31
- 52 Week High
- NVS $120.92
- MRK $134.63
- Technical
- Relative Strength Index (RSI)
- NVS 62.89
- MRK 44.17
- Support Level
- NVS $111.06
- MRK $75.59
- Resistance Level
- NVS $113.91
- MRK $78.20
- Average True Range (ATR)
- NVS 1.57
- MRK 2.03
- MACD
- NVS 0.45
- MRK 0.21
- Stochastic Oscillator
- NVS 98.99
- MRK 44.10
About NVS Novartis AG
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.